
Lyell Immunopharma (LYEL) Stock Forecast & Price Target
Lyell Immunopharma (LYEL) Analyst Ratings
Bulls say
Lyell Immunopharma is an innovative company with a promising pipeline of next-generation CAR-T therapies for hematologic malignancies and solid tumors, with rondecabtagene autoleucel and their novel GCC-targeted CAR-T product showing potential for improved efficacy and safety.However, they may face challenges with obtaining regulatory approval and competition in the market. With a strong technology and manufacturing process, the company has potential for long-term success in the cell therapy market.
Bears say
Lyell Immunopharma is at risk of facing lower than expected payer reimbursement due to high costs and potential production limitations for their CAR-T therapeutics, impacting their market potential. Additionally, concerns have been raised regarding the durability and persistence of their lead CAR-T candidate, rondecabtagene autoleucel, compared to other CAR-T products on the market. Key questions remain around the strength of correlations between ronde-cel's product composition and clinical durability, specifically in the PiNACLE study and when compared to other CD19/CD20 CAR-Ts.
This aggregate rating is based on analysts' research of Lyell Immunopharma and is not a guaranteed prediction by Public.com or investment advice.
Lyell Immunopharma (LYEL) Analyst Forecast & Price Prediction
Start investing in Lyell Immunopharma (LYEL)
Order type
Buy in
Order amount
Est. shares
0 shares